Rani Therapeutics

Rani Therapeutics

  • Founded: 2012
  • Location: San Jose, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin1
  • Therapy area: Neuroendocrine tumors/acromegaly
  • Drug types: END, ONC, BON, DRM, IMM, RHU
  • Lead product: RT-101 (partner: Celltrion)
  • Product link: https://www.ranitherapeutics.com/pipeline/
  • Funding: $73M IPO Jul 2021; $69M E Dec 2020; $53M Feb 2018; $142 total Feb 2018


ranitherapeutics.com

linkedin.com

job board


Short description:

Orally delivered Biologics

Drug notes:

RT-102 Clin1 osteoporosis; RT-111 Clin0 psoriasis; RT-105 Clin0 psoriatic arthritis; RT-110 Clin0 hypo-parathyroidism

Long description:

Rani Therapeutics is using advanced technology to enable oral delivery of large biologics. Many drugs can only be received via injection, which can be painful and inconvenient. Using expertise in engineering and material science, Rani has created the RaniPill capsule, which can be swallowed by patients in order to circumvent injections. The RaniPill capsule is a “robotic” pill that can inject drugs into the intestinal wall where there are no sharp pain receptors, thus making delivery painless. The intestinal wall is also highly vascularized to allow rapid drug absorption. Rani is looking to commercialize the RaniPill capsule to contain many large biologics that can be used to treat patients suffering from various chronic diseases.

Jobs:


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com